Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$4.29
+2.5%
$3.86
$1.78
$10.00
$292.11M0.58830,053 shs209,613 shs
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
$3.23
-2.4%
$4.00
$1.80
$8.94
$43.84MN/A183,533 shs436,653 shs
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
$8.14
+0.7%
$8.76
$4.44
$11.80
$170.02M-0.25133,263 shs9,022 shs
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$4.52
+1.8%
$4.48
$3.55
$16.11
$205.82M0.51295,505 shs38,926 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
+5.56%+5.03%+3.47%+45.64%+130.94%
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
+10.70%+2.80%+14.93%-1.19%+330,999,900.00%
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
+6.60%+7.45%-8.70%-5.16%+28.66%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
+5.46%+4.23%-12.60%+2.07%-60.60%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
2.1585 of 5 stars
3.51.00.00.00.63.30.6
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
2.5199 of 5 stars
3.80.00.00.03.21.70.0
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
3.261 of 5 stars
3.50.00.00.03.85.00.6
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
3.2833 of 5 stars
4.41.00.00.02.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3.00
Buy$15.00258.85% Upside
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
3.50
Strong Buy$23.50609.97% Upside
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
3.00
Buy$17.00110.40% Upside
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
2.82
Moderate Buy$15.60251.35% Upside

Current Analyst Ratings Breakdown

Latest MDCX, NVCT, YMAB, and CRVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00
7/1/2025
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00
6/23/2025
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00
6/9/2025
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00
5/29/2025
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00
5/29/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$20.00 ➝ $15.00
5/28/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$21.00 ➝ $18.00
5/22/2025
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
5/20/2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$12.00 ➝ $11.00
5/19/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $11.00
5/14/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $14.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/A$0.51 per shareN/A
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
N/AN/AN/AN/A$0.29 per shareN/A
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
N/AN/AN/AN/A$0.50 per shareN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$88.66M2.27N/AN/A$2.05 per share2.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$62.29M-$0.98N/AN/AN/AN/A-24.04%-13.90%8/5/2025 (Estimated)
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
-$11.16M-$1.16N/AN/AN/AN/A-380.03%-224.22%7/10/2025 (Estimated)
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
-$19M-$1.13N/AN/AN/AN/A-148.83%-95.60%8/5/2025 (Estimated)
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$29.67M-$0.64N/AN/AN/A-31.84%-30.59%-22.70%8/11/2025 (Estimated)

Latest MDCX, NVCT, YMAB, and CRVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.13N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
-$0.25N/AN/AN/AN/AN/A
7/10/2025N/A
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
-$0.39N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$0.22-$0.12+$0.10-$0.12$19.97 million$20.90 million
5/12/2025Q1 2025
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
-$0.23-$0.42-$0.19-$0.42N/AN/A
5/8/2025Q1 2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.13-$0.13N/A-$0.13N/AN/A
5/6/2025Q1 2025
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
-$0.30-$0.27+$0.03-$0.27N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/AN/A
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
N/AN/AN/AN/AN/A
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
N/AN/AN/AN/AN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/A
4.90
4.90
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
N/A
1.53
1.53
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
N/A
3.28
3.28
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/A
4.77
4.35

Institutional Ownership

CompanyInstitutional Ownership
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
46.64%
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
N/A
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
96.77%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
70.85%

Insider Ownership

CompanyInsider Ownership
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
28.50%
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
11.20%
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
30.52%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
19.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3068.17 million48.74 millionOptionable
Medicus Pharma Ltd stock logo
MDCX
Medicus Pharma
N/A13.57 million12.05 millionN/A
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
820.89 million14.52 millionNot Optionable
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
15045.28 million36.36 millionOptionable

Recent News About These Companies

YMAB Y-mAbs Therapeutics, Inc. - Seeking Alpha
Y mAbs Therapeutics News (YMAB) - Investing.com
Cantor Fitzgerald Comments on YMAB FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Corvus Pharmaceuticals stock logo

Corvus Pharmaceuticals NASDAQ:CRVS

$4.28 +0.11 (+2.51%)
As of 12:33 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Medicus Pharma stock logo

Medicus Pharma NASDAQ:MDCX

$3.23 -0.08 (-2.42%)
As of 12:12 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Nuvectis Pharma stock logo

Nuvectis Pharma NASDAQ:NVCT

$8.14 +0.06 (+0.74%)
As of 12:33 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Y-mAbs Therapeutics stock logo

Y-mAbs Therapeutics NASDAQ:YMAB

$4.52 +0.08 (+1.82%)
As of 12:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.